Access SITC 2021 Enduring Materials
You can now access SITC 2021 Enduring Materials on SITC CONNECT. Attendees will continue to have complimentary access to materials* and programs originally registered for, non-registrants can purchase content* for 50% off program registration rates.
*As permitted by presenters.
Tumor Immune Microenvironment:
A Holistic Approach Hybrid WorkshopThis workshop will focus on the tumor microenvironment and its possible impact on the development of future immunotherapies.
Download the new SITC Clinical Practice Guidelines (CPG) Mobile App! The first and only immunotherapy-specific clinical practice guidelines app featuring guideline content and expert panel recommendations in an easy-to-navigate format. The app includes interactive tools, bookmarks, and advanced search capabilities.Available for FREE for iOS and Android.
Cancer Immunotherapy Winter School, Jan. 24–28, 2022
SITC is pleased to host its fourth annual and first hybrid Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, Jan. 24–28, 2022.
New SITC Clinical Practice Guidelines Published
JITC Increases Impact Factor to 13.751The Journal for ImmunoTherapy of Cancer's (JITC) Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 5% percent of all journals published in the category of immunology and top 7% in the category of oncology.
A series of eight two-hour online seminars will feature experts in a given subject area to provide an overview of the current scientific knowledge about an area of immunotherapy. An interactive Q&A session will follow the topic overview, providing attendees the opportunity to ask in-depth questions of the faculty as well as offering a forum for networking and initiation of collaborations with others working in a similar field.
Comprised of several authoritative reviews of COVID-19 and Cancer Immunotherapy, this series, edited by Paolo Antonio Ascierto, MD and Jason D. Goldman, MD, MPH, will explore basic insights into the immunology of the novel coronavirus, repurposing of immune-based therapies including the effects of immune-oncology agents, and the affected cancer populations.
Join Alan Hutson, PhD, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
As research of cancer immunotherapy, and clinical use of these treatments, continues to grow, so too does the importance of clinicians sharing experiences and learning from others. We hope this community will afford you the opportunity. ------------------------------ ...
I wanted to remind my fellow community members that SITC is hosting the 2022 Cancer Immunotherapy Winter School in Austin, TX on Jan. 24–28, 2022 both in person and virtually. The Winter School , organized by Catherine Bollard, MBChB, MD, Christian ...
Sharing opportunities for all whom might be interested: The Cancer Research Institute is requesting applications for the Lloyd J. Old STAR Program . The STAR Program- S cientists TA king R isks-provides long-term funding to mid-career scientists, ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com